**DOCKET NO.:** WYNC-0330 (AM101206)

**Application No.:** 10/659,167

Office Action Dated: January 10, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims

## 1. (currently amended) A compound of Formula I:

wherein

Q is

$$R^{3} \qquad \text{or} \qquad R^{3}$$

$$R^{2} \qquad b$$

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms;

X and Y are, independently, hydrogen, hydroxy, halo, eyano, earboxamido, earboalkoxy of two to six earbon atoms, trifluoromethyl, alkyl of 1 to 6 earbon atoms, alkanoyl of 2 to 6 earbon atoms, alkanoyloxy of 2 to 6 earbon atoms, amino, mono or di-alkylamino in which each alkyl group has 1 to 6 earbon atoms, alkanomido of 2 to 6 earbon

**DOCKET NO.:** WYNC-0330 (AM101206)

**Application No.:** 10/659,167

Office Action Dated: January 10, 2006

atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms, or X and Y, taken together, form  $-N=C(R^4)-C(R^5)=N-$ ,  $-N=C(R^4)-C(R^5)=N-$ ,  $-N=C(R^4)-C(R^5)=N-$  or  $-N=C(R^4)-C(R^5)=N-$ 

R<sup>4</sup> and R<sup>5</sup> are, independently, hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R<sup>6</sup> is hydrogen or alkyl of 1 to 6 carbon atoms;

R<sup>7</sup>-is hydrogen, halo, trifluoromethyl, pentafluoroethyl, amino, mono- or di-alkylamino in which each alkyl group has 1-to 6 carbon atoms or alkyl of 1-to 6 carbon atoms;

R<sup>8</sup> is hydrogen, halo, trifluoromethyl, pentafluoroethyl, or alkyl of 1 to 6 earbon atoms;

Z is O, S, or  $NR^9$ , in which  $R^9$  is hydrogen or alkyl of 1 to 6 carbon atoms; n is an integer 0, 1, or 2;

m is an integer from 1 to 4. 2, provided that  $m + n \le 4$  and that when m = n = 2, and Q is b then X and Y are not NH-C( $\mathbb{R}^8$ )=CH-; and

p is an integer from 1 to 3-2, provided that p + n is 2 or 3; or a pharmaceutically acceptable salt thereof.

# 2-3. (cancelled)

- 4. (original) A compound according to claim 1, wherein Z is NR<sup>9</sup> or a pharmaceutically acceptable salt thereof.
- 5. (currently amended) A compound according to claim 1, wherein n is <del>0 or</del> 1 or a pharmaceutically acceptable salt thereof.
- 6. (currently amended) A compound according to claim 1, wherein m is 1 to 3 or a pharmaceutically acceptable salt thereof.

**PATENT** 

**DOCKET NO.:** WYNC-0330 (AM101206)

**Application No.:** 10/659,167

Office Action Dated: January 10, 2006

7. (currently amended) A compound according to claim 1, wherein p is 1 or 2 or a pharmaceutically acceptable salt thereof.

- 8. *(original)* A compound according to claim 1, wherein R<sup>1</sup> is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.
- 9. (original) A compound according to claim 1, wherein R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.
- 10. (original) A compound according to claim 1, wherein R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, amino or alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.

## 11. (cancelled)

12. (currently amended) A compound according to claim 1, wherein R<sup>6</sup> is hydrogen or alkyl of 1 to 3 carbon atoms, Z is NR<sup>9</sup> in which R<sup>9</sup> is hydrogen or alkyl of 1 to 3 carbon atoms, n is 0 or 1, m is 1 to 3 and p is 1 or 2 or a pharmaceutically acceptable salt thereof.

#### 13. (cancelled)

14. *(original)* A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

#### 15-16. (cancelled)

**DOCKET NO.:** WYNC-0330 (AM101206)

**Application No.:** 10/659,167

Office Action Dated: January 10, 2006

- 17. (original) A compound according to claim 1, wherein said compound is 2-[3-(1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- 18. (original) A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1-methyl-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- 19-24. (cancelled)
- 25. (original) A compound according to claim 1, wherein said compound is 8-Methyl-2-[3-(5-methyl-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- 26. (original) A compound according to claim 1, wherein said compound is the S enantiomer at the 2-aminomethyl-2,3-dihydro-1,4-benzodioxan moiety, substantially free of the R enantiomer of said compound.
- 27-29. (cancelled)
- 30. *(original)* A pharmaceutical composition, comprising: an effective amount of a compound according to claim 1; and a pharmaceutically acceptable carrier or excipient.
- 31. (new) A compound selected from the group consisting of:

  2-[3-(5-fluoro-1H-indol-3-ylmethyl)-piperidin-1-ylmethyl]-8-methyl-2,3dihydro-[1,4]dioxino[2,3-f]quinoline;

  2-[3-(6-fluoro-1H-indol-3-ylmethyl)-piperidin-1-ylmethyl]-8-methyl-2,3dihydro-[1,4]dioxino[2,3-f]quinoline;

**PATENT** 

**DOCKET NO.:** WYNC-0330 (AM101206)

**Application No.:** 10/659,167

Office Action Dated: January 10, 2006

2-({4-[(6-fluoro-1H-indol-1-yl)methyl]piperidin-1-yl})-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline;

2-({4-[(6-fluoro-1H-indol-1-yl)ethyl]piperidin-1-yl})-8-ethyl-2,3-dihydro[1,4] dioxino[2,3-f]quinoline;

1-[(1-{[8-methyl-2,3-dihydro[1,4]-dioxino[2,3-f]quinolin-2-yl]methyl})
piperidin-4-yl]-1H-indole-6-carbonitrile;

2-[3-(6-fluoro-indol-1-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline;

2-{3-[2-(6-fluoro-indol-1-yl)-ethyl]-azetidin-1-ylmethyl}-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline;

1-{2-[1-(8-methyl-2,3-dihydro-[1,4]-dioxino[2,3-f]quinolin-2-ylmethyl)-azetinin-3-yl]-ethyl}-1H-indole-6-carbonitrile; and pharmaceutically acceptable salts thereof.